Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

VolitionRx Ltd set for US$10.6mln cash boost after placing

Thursday, October 6, 2016 6:33
% of readers think this story is Fact. Add your two cents.

Cancer diagnostics specialist VolitionRx Ltd (NYSE:VNRX) has brought in around US$10.6mln after closing the  previously announced share offer.

The group sold all the shares on offer, priced at $5 each, namely 2.25mln.

The company plans to use the net proceeds to continue its product development, clinical studies, commercialsation and for working capital.

In September, VolitionRx said it expects to receive European Union CE Marking on its Nu. Q colorectal cancer blood test later this year.

Receiving the CE mark would pave the way for a product launch in Europe in 2017, providing European healthcare practitioners with a much more accurate blood test than the current industry standard, which has a poor record in terms of identifying patients who genuinely need to be sent for colonoscopies.

Colorectal cancer is ranked second among all newly-diagnosed cancers and responsible for around 215,000 deaths in Europe each year. It is, of course, a big problem also in America also and the firm  has told Proactive Investors that the product would also be released in the USA when the time is right.

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.